Clinical trials

  • SAR446523 for Relapsed/refractory multiple myeloma
  • Olverembatinib for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)
  • CARVEDILOL for Compensated liver cirrhosis (Child-Pugh A5–B8) | Clinically significant portal hypertension
  • OLVEREMBATINIB for Chronic myeloid leukemia (chronic phase)
  • 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one for Metastatic castration-resistant prostate cancer
  • Human papilloma L2 antigen; cyclic di-AMP (adjuvant) for Human papillomavirus (HPV) infection (prophylaxis)
  • Azacitidine for Myelodysplastic syndrome|Mixed myelodysplastic/myeloproliferative neoplasm|Acute myeloid leukemia
  • ETEPLIRSEN for Duchenne muscular dystrophy
  • ZOLBETUXIMAB for Gastric adenocarcinoma | Gastroesophageal junction adenocarcinoma
  • ELAMIPRETIDE TRIHYDROCHLORIDE for Dry age-related macular degeneration (Dry AMD)
  • RITUXIMAB for Follicular lymphoma
  • MIRIKIZUMAB for Crohn's disease